Study guide
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME)
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME)
Key Takeaways Explain This Topic AI
Passive transcellular diffusion depends on the fraction of un-ionized, lipophilic drug according to the Henderson-Hasselbalch equation and Fick's first law.
P-glycoprotein (ABCB1) is an ATP-dependent apical efflux transporter in the gut, liver, kidneys, and blood-brain barrier; its induction reduces systemic drug exposure, while its inhibition increases toxicity risks.
Hypoalbuminemia increases the pharmacologically active unbound (free) fraction of acidic drugs like phenytoin and warfarin without altering total drug clearance, necessitating free drug monitoring or adjusted concentration formulas (Winter-Tozer).
Phase I cytochrome P450 monooxygenases (especially CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2) and Phase II conjugating enzymes dictate metabolic clearance and are prime sites for genetic polymorphisms and clinically critical drug-drug interactions.
Renal clearance comprises glomerular filtration of unbound drug, active transporter-mediated tubular secretion (OATs and OCTs), and passive pH-dependent tubular reabsorption.
Last updated: August 2026
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME)
Pharmacokinetics describes the quantitative time course of drug absorption, distribution, metabolism, and excretion (ADME)—frequently summarized as what the body does to the drug. A rigorous understanding of ADME principles is fundamental for evaluating therapeutic efficacy, anticipating drug-drug interactions, and adjusting dosage regimens in clinical pharmacy practice.
1. Physicochemical and Physiological Determinants of Drug Absorption
Drug absorption is the movement of an active pharmaceutical ingredient from its site of administration into the systemic circulation. For oral solid dosage forms, absorption requires drug dissolution into gastrointestinal fluids followed by transport across the gastrointestinal epithelial membrane.
Membrane Transport Mechanisms +-----------------------------------------------------------------------------------+
- | MEMBRANE PERMEATION ROUTES |
- +-----------------------------------------------------------------------------------+
- | 1. Passive Transcellular Diffusion : Small, lipophilic, un-ionized molecules |
- | 2. Paracellular Transport : Small, hydrophilic molecules (<200 Da) |
- | 3. Carrier-Mediated Influx (OATP) : Facilitated diffusion / active transport |
- | 4. Efflux Transport (P-gp, BCRP) : ATP-dependent active extrusion into lumen |
- | 5. Transcytosis / Endocytosis : Macromolecules, peptides, nanoparticles |
- +-----------------------------------------------------------------------------------+
Passive Transcellular Diffusion : The primary pathway for most lipophilic, low-molecular-weight drugs. The rate of diffusion across the apical membrane is governed by Fick's First Law of Diffusion : d Q d t = D ⋅ A ⋅ K ⋅ ( C lumen − C plasma ) h \frac{dQ}{dt} = \frac{D \cdot A \cdot K \cdot (C_{\text{lumen}} - C_{\text{plasma}})}{h} d t d Q = h D ⋅ A ⋅ K ⋅ ( C lumen − C plasma )
Where d Q / d t dQ/dt d Q / d t represents the rate of drug transfer across the membrane, D D D is the diffusion coefficient of the drug, A A A is the functional surface area of the intestinal membrane (approximately 30 m 2 30\text{ m}^2 30 m 2 in adults due to microvilli), K K K is the lipid-water partition coefficient, C lumen − C plasma C_{\text{lumen}} - C_{\text{plasma}} C lumen − C plasma is the concentration gradient, and h h h is membrane thickness.
The pH-Partition Hypothesis and Ionization Equivalence : Biological membranes are predominantly permeable to the lipid-soluble, un-ionized form of weak organic acids and bases. The extent of ionization is defined by the Henderson-Hasselbalch equations : For Weak Acids: pH = p K a + log ( [ Ionized Base ( A − ) ] [ Un-ionized Acid ( H A ) ] ) \text{For Weak Acids: } \text{pH} = \text{p}K_a + \log\left(\frac{[\text{Ionized Base (}A^-)]}{[\text{Un-ionized Acid (}HA)]}\right) For Weak Acids: pH = p K a + lo g ( [ Un-ionized Acid ( H A )] [ Ionized Base ( A − )] ) For Weak Bases: pH = p K a + log ( [ Un-ionized Base ( B ) ] [ Ionized Conjugate Acid ( B H + ) ] ) \text{For Weak Bases: } \text{pH} = \text{p}K_a + \log\left(\frac{[\text{Un-ionized Base (}B)]}{[\text{Ionized Conjugate Acid (}BH^+)]}\right) For Weak Bases: pH = p K a + lo g ( [ Ionized Conjugate Acid ( B H + )] [ Un-ionized Base ( B )] )
Clinical Application (Ion Trapping) : When a pH differential exists across biological membranes, basic drugs concentrate in acidic fluid compartments (e.g., breast milk, gastric secretions, prostatic fluid), whereas acidic drugs accumulate in basic compartments (e.g., systemic plasma relative to intracellular space).
Membrane Transporters in Absorption
Efflux Transporters (ATP-Binding Cassette / ABC Family) : P-glycoprotein (P-gp/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) are expressed on the apical surface of enterocytes. They utilize ATP hydrolysis to pump absorbed drugs back into the intestinal lumen, acting as a biochemical barrier to oral bioavailability.
P-gp Substrates : Digoxin, dabigatran etexilate, cyclosporine, tacrolimus, colchicine, loperamide.
P-gp Inhibitors : Clarithromycin, itraconazole, verapamil, amiodarone, quinidine, ritonavir. Co-administration increases substrate plasma concentrations, risking toxicity.
P-gp Inducers : Rifampin, carbamazepine, St. John's wort (Hypericum perforatum), phenytoin. Co-administration accelerates efflux, precipitating therapeutic failure.
2. Presystemic Extraction and First-Pass Metabolism
Before an orally administered drug reaches the systemic arterial circulation, it must pass sequentially through the gastrointestinal mucosa, the mesenteric venules, the hepatic portal vein, and the liver parenchymal tissue. [Drug in GI Lumen] ---> [Enterocyte Uptake]
- |
- v
- [Gut-Wall CYP3A4 / Phase II] ---> Excreted / Inactive
- |
- v (Mesenteric / Portal Circulation)
- [Hepatic First-Pass]
- |
- +------------------+------------------+
- | |
- v v
- [Hepatic CYP450 / UGT] [Systemic Circulation]
- (High Extraction: Propranolol, Morphine) (Active Drug Available)
Intestinal First-Pass : Enterocytes contain substantial concentrations of CYP3A4/5 and Phase II enzymes. For instance, midazolam and cyclosporine undergo extensive pre-hepatic gut metabolism.
Hepatic Extraction Ratio ( E H E_H E H ) : Represents the fraction of drug entering the liver that is irreversibly removed during a single pass: E H = C inflow − C outflow C inflow E_H = \frac{C_{\text{inflow}} - C_{\text{outflow}}}{C_{\text{inflow}}} E H = C inflow C inflow − C outflow
Extraction Category Extraction Ratio ( E H E_H E H ) Systemic Bioavailability ( F F F ) Representative Drugs Clinical Implication
High Extraction E H > 0.7 E_H > 0.7 E H > 0.7 Low ( F < 30 % F < 30\% F < 30% ) Morphine, propranolol, lidocaine, verapamil, nitroglycerin Oral dose is substantially higher than IV dose; clearance is blood-flow dependent.
Intermediate E H = 0.3 − 0.7 E_H = 0.3 - 0.7 E H = 0.3 − 0.7 Moderate ( F = 30 − 70 % F = 30-70\% F = 30 − 70% ) Codeine, nortriptyline, diltiazem Sensitive to changes in intrinsic clearance and hepatic blood flow.
Low Extraction E H < 0.3 E_H < 0.3 E H < 0.3 High ( F > 70 % F > 70\% F > 70% ) Warfarin, phenytoin, diazepam, theophylline Clearance is capacity-limited and sensitive to enzyme induction/inhibition and protein binding.
3. Apparent Volume of Distribution ( V d V_d V d ) and Tissue Binding
The apparent volume of distribution ( V d V_d V d ) is a proportionality constant that relates the total mass of drug in the body ( A body A_{\text{body}} A body ) to the measured drug concentration in plasma ( C p C_p C p ): V d = Dose IV C 0 = A body C p V_d = \frac{\text{Dose}_{\text{IV}}}{C_0} = \frac{A_{\text{body}}}{C_p} V d = C 0 Dose IV = C p A body
Physiologically, V d V_d V d is determined by the actual anatomical plasma volume ( V p ≈ 3 L V_p \approx 3\text{ L} V p ≈ 3 L in a 70 kg 70\text{ kg} 70 kg adult), extracellular water ( V ECW ≈ 14 L V_{\text{ECW}} \approx 14\text{ L} V ECW ≈ 14 L ), total body water ( V TBW ≈ 42 L V_{\text{TBW}} \approx 42\text{ L} V TBW ≈ 42 L ), and the fraction of unbound drug in plasma ( f u f_u f u ) relative to tissue ( f u t f_{ut} f u t ): V d = V p + V t ⋅ ( f u f u t ) V_d = V_p + V_t \cdot \left(\frac{f_u}{f_{ut}}\right) V d = V p + V t ⋅ ( f u t f u ) +------------------------------------------------------------------------------------+
- | PHYSIOLOGICAL FLUID VOLUMES vs. DRUG EXAMPLES |
- +------------------------------------------------------------------------------------+
- | Vd ~ 3 - 5 L (Vascular Pool) : Heparin, Monoclonal Antibodies |
- | Vd ~ 14 - 18 L (Extracellular Fluid): Aminoglycosides, Beta-Lactams, Vancomycin |
- | Vd ~ 40 - 45 L (Total Body Water) : Ethanol, Lithium, Theophylline |
- | Vd >> 500 L (Extensive Tissue) : Digoxin (~500 L), Amiodarone (~5000 L), TCAs |
- +------------------------------------------------------------------------------------+
- Plasma Protein Binding Dynamics
Only unbound (free) drug can cross biological membranes, interact with pharmacological receptors, and undergo glomerular filtration or hepatic biotransformation.
Major Binding Macromolecules :
Albumin : Primarily binds neutral and acidic drugs (e.g., warfarin, phenytoin, valproic acid, methotrexate, salicylates, ceftriaxone).
α 1 \alpha_1 α 1 -Acid Glycoprotein (AAG) : An acute-phase reactant synthesized by hepatocytes that binds basic drugs (e.g., lidocaine, propranolol, verapamil, quinidine, tricyclic antidepressants). AAG concentrations rise markedly during inflammation, surgery, trauma, and malignancy.
Lipoproteins : Bind lipophilic basic compounds (e.g., cyclosporine, amiodarone).
Hypoalbuminemia and the Winter-Tozer Correction :
In conditions of reduced serum albumin (cirrhosis, nephrotic syndrome, critical illness, severe burns, protein malnutrition), the total measured serum concentration of highly bound drugs declines because clearance of total drug increases, but the absolute unbound concentration ( C u = f u ⋅ C total C_u = f_u \cdot C_{\text{total}} C u = f u ⋅ C total ) remains relatively constant. For phenytoin (which is normally 90 % 90\% 90% protein-bound, f u = 0.10 f_u = 0.10 f u = 0.10 ), the Winter-Tozer equation estimates the normalized total concentration at normal albumin ( 40 g/L 40\text{ g/L} 40 g/L or 4.0 g/dL 4.0\text{ g/dL} 4.0 g/dL ): In Conventional Units (Albumin in g/dL): C adj = C obs ( 0.2 ⋅ Albumin ) + 0.1 \text{In Conventional Units (Albumin in g/dL): } C_{\text{adj}} = \frac{C_{\text{obs}}}{(0.2 \cdot \text{Albumin}) + 0.1} In Conventional Units (Albumin in g/dL): C adj = ( 0.2 ⋅ Albumin ) + 0.1 C obs In Canadian SI Units (Albumin in g/L): C adj = C obs ( 0.02 ⋅ Albumin ) + 0.1 \text{In Canadian SI Units (Albumin in g/L): } C_{\text{adj}} = \frac{C_{\text{obs}}}{(0.02 \cdot \text{Albumin}) + 0.1} In Canadian SI Units (Albumin in g/L): C adj = ( 0.02 ⋅ Albumin ) + 0.1 C obs
ESRD Modification (CrCl < 10 mL/min < 10\text{ mL/min} < 10 mL/min ) : Due to reduced binding affinity from uremic toxins, the slope constant changes: C adj = C obs / [ ( 0.01 ⋅ Albumin ) + 0.1 ] C_{\text{adj}} = C_{\text{obs}} / [(0.01 \cdot \text{Albumin}) + 0.1] C adj = C obs / [( 0.01 ⋅ Albumin ) + 0.1 ] (using g/L \text{g/L} g/L ). Failure to correct leads to inappropriate dosage escalations and neurotoxicity.
4. Hepatic Biotransformation (Phase I and Phase II Reactions)
Metabolism converts lipophilic xenobiotics into more hydrophilic, water-soluble metabolites that can be excreted in urine or bile. +-------------------------+
- | Parent Xenobiotic |
- +-------------------------+
- |
- v
- +-------------------------------------------------------+
- | Phase I (Functionalization: Oxidation, Hydrolysis) |
- | Enzymes: CYP450, FMO, Alcohol Dehydrogenase, Esterase |
- +-------------------------------------------------------+
- |
- v
- +-------------------------------------------------------+
- | Phase II (Conjugation: Glucuronidation, Sulfation) |
- | Enzymes: UGT, SULT, NAT, GST, TPMT |
- +-------------------------------------------------------+
- |
- v
- +-------------------------+
- | Excretable Metabolite |
- | (Urine / Bile) |
- +-------------------------+
- Cytochrome P450 Enzyme System
The CYP450 superfamily accounts for > 75 % >75\% > 75% of all drug biotransformations. The table below details high-yield enzymes for the PEBC examination:
CYP Isozyme Major Substrates Potent Inhibitors Potent Inducers
CYP1A2 Theophylline, clozapine, olanzapine, tizanidine, duloxetine Fluvoxamine, ciprofloxacin, enoxacin Polycyclic aromatic hydrocarbons (tobacco smoke, charbroiled meats), omeprazole, carbamazepine
CYP2C9 (S)-Warfarin, phenytoin, celecoxib, glyburide, glipizide Fluconazole, amiodarone, sulfamethoxazole, metronidazole Rifampin, carbamazepine, phenobarbital, St. John's wort
CYP2C19 Clopidogrel (prodrug activation), omeprazole, lansoprazole, diazepam, escitalopram Omeprazole, esomeprazole, fluvoxamine, fluconazole, ticlopidine Rifampin, carbamazepine
CYP2D6 Metoprolol, carvedilol, codeine/tramadol (prodrug activation), venlafaxine, haloperidol, tamoxifen Fluoxetine, paroxetine, bupropion, quinidine, duloxetine Non-inducible (regulated primarily by genetics)
CYP2E1 Acetaminophen, ethanol, halothane, enflurane Disulfiram, 4-methylpyrazole (fomepizole) Chronic ethanol consumption, isoniazid
CYP3A4/5 Simvastatin, atorvastatin, cyclosporine, tacrolimus, CCBs (amlodipine, diltiazem), rivaroxaban, apixaban Clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, cobicistat, grapefruit juice Rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, efavirenz, modafinil
Phase II Conjugation Enzymes and Pharmacogenetics
UDP-Glucuronosyltransferases (UGTs) : UGT1A1 conjugates bilirubin, SN-38 (irinotecan active metabolite), and dolutegravir. UGT2B7 metabolizes morphine to morphine-3-glucuronide (M3G, neurotoxic) and morphine-6-glucuronide (M6G, potent analgesic).
N-Acetyltransferases (NAT1, NAT2) : NAT2 metabolizes isoniazid, hydralazine, procainamide, and dapsone. "Slow acetylators" have elevated drug concentrations, predisposing them to peripheral neuropathy (isoniazid) and drug-induced lupus erythematosus (hydralazine, procainamide).
Thiopurine S-Methyltransferase (TPMT) : Inactivates 6-mercaptopurine and azathioprine. Patients homozygous for non-functional alleles accumulate thioguanine nucleotides, resulting in fatal bone marrow suppression unless the dose is reduced by 80 − 90 % 80-90\% 80 − 90% .
5. Renal and Non-Renal Clearance Pathways
Total systemic clearance ( C L CL C L ) is the sum of all organ-specific clearance mechanisms: C L = C L renal + C L hepatic + C L pulmonary + C L other CL = CL_{\text{renal}} + CL_{\text{hepatic}} + CL_{\text{pulmonary}} + CL_{\text{other}} C L = C L renal + C L hepatic + C L pulmonary + C L other
Renal Clearance Mechanisms Renal Clearance ( C L R ) = ( f u ⋅ G F R ) + C L secretion − Rate of Reabsorption \text{Renal Clearance } (CL_R) = (f_u \cdot GFR) + CL_{\text{secretion}} - \text{Rate of Reabsorption} Renal Clearance ( C L R ) = ( f u ⋅ GFR ) + C L secretion − Rate of Reabsorption
Glomerular Filtration : Passive filtration of unbound drugs across the fenestrated glomerular capillary membrane ( M r < 60 kDa M_r < 60\text{ kDa} M r < 60 kDa ). The maximum filtration clearance is f u ⋅ G F R f_u \cdot GFR f u ⋅ GFR .
Active Tubular Secretion : Energy-dependent transport from peritubular capillaries into the proximal tubular lumen via:
Organic Anion Transporters (OAT1/OAT3) : Penicillins, cephalosporins, methotrexate, loop diuretics, probenecid. Interaction : Probenecid blocks OAT, dramatically increasing penicillin and methotrexate levels.
Organic Cation Transporters (OCT2 / MATE1/2-K) : Metformin, cimetidine, trimethoprim. Interaction : Cimetidine and trimethoprim inhibit OCT2/MATE, elevating serum creatinine (pseudo-renal impairment) and metformin concentrations.
Passive Tubular Reabsorption : Lipophilic, un-ionized molecules are reabsorbed down concentration gradients in the distal tubule.
Urinary Alkalinization : Intravenous administration of sodium bicarbonate raises urine pH to 7.5 − 8.5 7.5 - 8.5 7.5 − 8.5 . For weak acids like salicylates ( p K a ≈ 3.0 − 3.5 \text{p}K_a \approx 3.0-3.5 p K a ≈ 3.0 − 3.5 ) and methotrexate , ionization increases in alkaline urine, trapping them in the tubular lumen and accelerating renal excretion.
Biliary Clearance and Enterohepatic Recirculation
Drugs conjugated to glucuronide in the liver (e.g., ethinyl estradiol, mycophenolic acid, morphine, ezetimibe) are excreted into the bile and emptied into the duodenum. Intestinal bacterial flora produce β \beta β -glucuronidase , which hydrolyzes the conjugate, liberating the parent drug to be reabsorbed. Broad-spectrum antibiotics can suppress gut microflora, interrupting this cycle and lowering plasma drug levels.